Sagent Launches Oxaliplatin for Injection

Sagent Pharmaceuticals announced the launch of Oxaliplatin for Injection, the generic version of Sanofi-Aventis‘ Eloxatin.

Oxaliplatin, an alkylating agent, is indicated for adjuvant treatment for Stage III colon cancer in patients who have undergone complete resection of the primary tumor (in combination with infusional 5-FU/LV), and for treatment of advanced colorectal cancer (in combination with infusional 5-FU/LV).

Oxaliplatin for Injection is available in two latex-free vial presentations featuring the company’s PreventIV Measures packaging and labeling designed to aid in the reduction of medication errors.

For more information call (866) 625-1618 or visit www.sagentpharma.com.